Zoltán Szállási

Semmelweis University

Full Professor(heuristic)

Cancer Genomics and Diagnostics · Cancer Research

h-index83

i10-index197

Publications643

Citations48,273

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 36

Supplementary Figure S1 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
2026-06-17
Supplementary Table S4 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
2026-06-17
Supplementary Figure S5 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
2026-06-17
Supplementary Figure S2 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
2026-06-17
Supplementary Figure S4 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
2026-06-17
Data from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
2026-06-17
Supplementary Table S3 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
2026-06-17
Supplementary Table S2 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
2026-06-17
Supplementary Table S1 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
2026-06-17
Supplementary Figure S6 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
2026-06-17
Supplementary Figure S3 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
2026-06-17
RETRACTED: Sharad et al. Analysis of PMEPA1 Isoforms (a and b) as Selective Inhibitors of Androgen and TGF-β Signaling Reveals Distinct Biological and Prognostic Features in Prostate Cancer. Cancers 2019, 11, 1995
Cancers · 2026-03-04
Genomic characterization of therapy-associated polyposis reveals an alkylating mutational signature from prior treatment
medRxiv · 2026-02-22
Identification of an ERCC2 mutation associated mutational signature of nucleotide excision repair deficiency in targeted panel sequencing data
bioRxiv (Cold Spring Harbor Laboratory) · 2026-02-19
A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM , BRCA1 , BRCA2 , PALB2 , and CHEK2
Clinical Cancer Research · 2026-02-13 · 1 citations
Generation of a comprehensive epigenomic atlas in clear cell renal cell carcinoma informs kidney cancer progression and heritability
Cell Reports · 2026-02-01
A multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinoma
medRxiv · 2026-01-30
Zero-shot biological reasoning with open-weights large language models reproduces CRISPR screen based prediction of synthetic lethal interactions
bioRxiv (Cold Spring Harbor Laboratory) · 2026-01-30
Abstract PR017: Dissecting the role of CHD1 as a key regulator of pro-metastatic transcriptional reprogramming in BRCA2-mutant prostate cancer
Cancer Research · 2026-01-20
Long-term exposure to the ethanol-derived metabolite acetaldehyde elevates structural genomic alterations but not base substitutions
Communications Biology · 2026-01-17

Open author page on OpenAlex →